Roche plans to present research on Alzheimer’s treatments and blood tests at the Clinical Trials on Alzheimer’s Disease congress in Boston on 16–19 November. The company’s programme includes updated early-stage findings for trontinemab and the design of a prevention study that has begun enrolling participants.
The company will also describe a phase 2 trial of the experimental oral medicine RG6434 in people with early symptoms. It targets a pathway linked to inflammation. Separate presentations will examine blood tests that measure pTau217 or pTau181 and how they might fit into diagnostic pathways.
Changes in amyloid or other biomarkers answer a different question from whether people retain memory or daily function for longer. The announcement sets out what will be presented. The strength and clinical relevance of the evidence can be judged from the full presentations.
